



Treprostinil injection (Remodulin®); Treprostinil

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

**The proposal is to add text/statements in red and to delete text/statements with strikethrough:
POLICY**

INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

- Treatment of pulmonary arterial hypertension (PAH; World Health Organization [WHO] Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with New York Heart Association (NYHA) Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH, PAH associated with congenital systemic-to-pulmonary shunts, or PAH associated with connective tissue diseases.
- In patients with PAH requiring transition from epoprostenol, to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug ~~should be carefully considered~~ prior to transition.

All other indications are considered experimental/investigational and not medically necessary.

PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a pulmonologist or cardiologist.

COVERAGE CRITERIA FOR INITIAL APPROVAL

Pulmonary Arterial Hypertension (PAH)

Authorization of 12 months may be granted for treatment of PAH when ALL of the following criteria are met:

- Member has PAH defined as WHO Group 1 class of pulmonary hypertension (refer to Appendix).
- PAH was confirmed by either **of the following: criterion (1) or criterion (2) below:**
 - Pretreatment right heart catheterization with all of the following results:
 - Mean pulmonary arterial pressure (mPAP) > 20 mmHg
 - Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
 - Pulmonary vascular resistance (PVR) **>2** ~~≥3~~ Wood units. **For pediatric members, in adult members or pulmonary vascular resistance index (PVRI) > ≥ 3 Wood units x m² is also acceptable.**
~~in pediatric members~~
 - For infants less than one year of age, PAH was confirmed by Doppler echocardiogram if right heart catheterization cannot be performed.

Medical Policy Manual **Draft Revised Policy: Do Not Implement**

CONTINUATION OF THERAPY

Authorization of 12 months may be granted for members with an indication listed in **the coverage criteria** section III who are currently receiving the requested medication through a paid pharmacy or medical benefit, and who are experiencing benefit from therapy as evidenced by disease stability or disease improvement.

APPENDIX

WHO Classification of Pulmonary Hypertension (PH)

Note: Patients with heritable PAH or PAH associated with drugs and toxins might be long-term responders to calcium channel blockers.

Group 1: Pulmonary Arterial Hypertension (PAH)

- Idiopathic PAH
 - **Long-term responders to calcium channel blockers**
- Heritable PAH
- **Associated with** drugs and toxins-induced PAH
- PAH Associated with:
 - Connective tissue disease
 - Human immunodeficiency virus (HIV) infection
 - Portal hypertension
 - Congenital heart disease
 - Schistosomiasis

1.5 PAH long-term responders to calcium channel blockers

- PAH with ~~one~~ features of venous/capillary(pulmonary veno-occlusive disease [PVOD]/pulmonary capillary hemangiomatosis [PCH]) involvement
- Persistent PH of the newborn ~~syndrome~~

Group 2: PH associated with ~~due to~~ Left Heart Disease

- **Heart Failure:**
 - ~~PH due to heart failure~~ With preserved left ventricular ejection fraction (LVEF)
 - ~~PH due to heart failure~~ With reduced **or mildly reduced ejection fraction** LVEF
 - **Cardiomyopathies with specific etiologies (i.e., hypertrophic, amyloid, Fabry disease, and Chagas disease)**
- Valvular heart disease:
 - **Aortic valve disease**
 - **Mitral valve disease**
 - **Mixed valvular disease**
- Congenital/acquired cardiovascular conditions leading to post-capillary PH

Group 3: PH associated with ~~due to~~ Lung Diseases and/or Hypoxia

- **Chronic Obstructive pulmonary lung disease (COPD) and/or emphysema**
- **Interstitial Restrictive lung disease**
- **Combined pulmonary fibrosis and emphysema**
- ~~3.3 Other lung disease with mixed restrictive/obstructive pattern~~
- **Other parenchymal lung diseases (i.e., parenchymal lung diseases not included in Group 5)**
- **Nonparenchymal restrictive diseases:**
 - **Hypoventilation syndromes**
 - **Pneumonectomy**



Medical Policy Manual

Draft Revised Policy: Do Not Implement

- Hypoxia without lung disease (e.g., high altitude)
- Developmental lung ~~diseases~~ disorders

Group 4: PH associated with ~~due to~~ Pulmonary Artery Obstructions

- Chronic thromboembolic PH
- Other pulmonary artery obstructions:
 - Sarcomas (high- or intermediate-grade) or angiosarcoma)
 - Other malignant tumors (e.g., renal carcinoma, uterine carcinoma, germ-cell tumors of the testis)

Renal carcinoma

Uterine carcinoma

Germ cell tumors of the testis

Other tumors

- Non-malignant tumors (e.g. uterine leiomyoma)

Uterine leiomyoma

- Arteritis without connective tissue disease
- Congenital pulmonary artery stenosis

Parasites

- Hydatidosis

Group 5: PH with Unclear and/or Multifactorial Mechanisms

- Hematologic disorders, including inherited and acquired ÷ chronic hemolytic anemia and chronic myeloproliferative disorders
- Systemic and metabolic disorders: Sarcoidosis, pulmonary Langerhans cell histiocytosis, and Gaucher disease, glycogen storage disease, neurofibromatosis type 1, sarcoidosis
- Metabolic disorders, including glycogen storage diseases and Gaucher disease
- Others: Chronic renal failure with or without hemodialysis, fibrosing mediastinitis
- Pulmonary tumor thrombotic microangiopathy
- Fibrosing mediastinitis
- Complex congenital heart disease

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

REFERENCES

1. Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corp.; October 2023.
2. Treprostinil [package insert]. Princeton, NJ: Sandoz, Inc.; April 2023.
3. ~~McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus~~



Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. *J Am Coll Cardiol.* 2009;53(17):1573-1619.

4. Badesch DB, Champion HC, Gomez-Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. *J Am Coll Cardiol.* 2009;54:S55-S66.
5. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults. CHEST guideline and expert panel report. *Chest.* 2014;46(2):449-475.
6. Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. *Circulation.* 2015;132(21):2037-99.
7. Klinger, JR., Elliott, CG, Levine, DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guidelines and Expert Panel Report. *Chest.* 2019;155(3): 565-586.
8. Galie, N., McLaughlin, VV, Rubin, LJ, Simonneau, G. An overview of the 6th World Symposium on Pulmonary Hypertension. *Eur Respir J* 2019; 53: 1802148; DOI: 10.1183/13993003.02148-2018. Published 24 January 2019.
9. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J* 2019;53:1801913; doi:10.1183/13993003.01913-2018.
10. Kovacs G, Bartolome S, Denton CP, et al. Definition, classification and diagnosis of pulmonary hypertension. *Eur Respir J.* 2024;64(4):2401324. doi: 10.1183/13993003.01324-2024.
11. Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. *Eur Respir J.* 2024;64(4):2401325. doi: 10.1183/13993003.01325-2024.
12. Ivy D, Rosenzweig EB, Abman SH, et al. Embracing the challenges of neonatal and pediatric pulmonary hypertension. *Eur Respir J.* 2024;64(4):2401345. doi: 10.1183/13993003.01345-2024.

EFFECTIVE DATE

ID_CHS